PhamAsia News Top Editors' Picks Of 2010
This article was originally published in PharmAsia News
Executive Summary
More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia
You may also be interested in...
China Signals Need For Private Investment To Support Its Healthcare Reforms; Private Insurance Options Likely To Widen
SHANGHAI - China recently lifted a ban on foreign investment in medical institutes to support its $124 billion healthcare reforms and the establishment of wholly foreign-owned hospitals and clinics. The move by the Chinese government is being read as a signal that China may open more of the country's healthcare industry to foreign investment
Patent Cliff Leads Pfizer To Begin Direct Sales To Pharmacies; Aussie Distributors Reeling
SINGAPORE - Pfizer Australia will begin direct sales of its prescription medicines to pharmacies in early 2011, cutting out distributors as part of a global battle to go head-to-head against generic copies of blockbuster drugs like Lipitor that face patent expiry in the coming years
Takeda Shows Signs Of Undergoing Corporate Shift In Decision-making
TOKYO - Takeda has incrementally made a number of organizational announcements in recent months hinting at a shift in the company's outlook to R&D investment and alliance-building in new markets